PMVP Pengajuan SEC - PMV Pharmaceuticals, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1699382

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PMV Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 7, 2025	EX-99.1	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights • PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis data • Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up • Cash, cash equivalents, and marketable secur
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PMV Pharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commissio
June 9, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2025 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission F
May 9, 2025	EX-10.3	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated November 5, 2025, by and between the Registrant and Robert Ticktin. Exhibit 10.3 Change in Control and Severance Policy (the "Policy") Amended and Restated Participation Agreement This Amended and Restated Participation Agreement ("Agreement") is made and entered into by and between Rob Ticktin, on the one hand, and PMV Pharmaceuticals, Inc. (the "Company") on the other. In connection with your appointment as a Company officer, you are entitled to receive certain
May 9, 2025	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights • Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors • Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for ap
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
May 9, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission F
May 9, 2025	EX-10.1	Amended Outside Director Compensation Policy. Exhibit 10.1 Reviewed & Updated by PMV Board as of: April 21, 2025 (“Updated Effective Date”) PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY PMV Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain an
May 9, 2025	EX-10.2	Offer Letter Agreement dated November 5, 2025, by and between the Registrant and Robert Ticktin. Exhibit 10.2 November 5, 2024 Robert Ticktin c/o PMV Pharmaceuticals Dear Robert, This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”), and amends and restates in full your earlier Employment Letter August 11, 2020, , reflecting your promotion and related compensation changes. This Agreement is effective as of the
April 25, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
March 3, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K c UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ! (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMAC
March 3, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
March 3, 2025	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands) PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights • Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.
March 3, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 PMV PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Updated February 26, 2025) A. POLICY OVERVIEW PMV Pharmaceuticals, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its
February 21, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm256962d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. Th
January 28, 2025	S-8	As filed with the Securities and Exchange Commission on January 28, 2025 As filed with the Securities and Exchange Commission on January 28, 2025 Registration No.
January 28, 2025	EX-FILING FEES	Calculation of Filing Fee Table EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PMV Pharmaceuticals, Inc.
December 12, 2024	SC 13G	PMVP / PMV Pharmaceuticals, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G 1 pmvp13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103 (CUSIP
November 27, 2024	424B3	Up to $113,792,846.40 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-283349 PROSPECTUS SUPPLEMENT Up to $113,792,846.40 Shares of Common Stock We previously entered into an Open Market Sale AgreementSM, or sales agreement, dated October 4, 2021, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sal
November 25, 2024	CORRESP	November 25, 2024 November 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: PMV Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 20, 2024 File No. 333-283349 Acceleration Request Requested Date: Wednesday, November 27, 2024 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen
November 20, 2024	EX-FILING FEES	Calculation of Filing Fee Tables EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) PMV Pharmaceuticals, Inc.
November 20, 2024	S-3	As filed with the Securities and Exchange Commission on November 20, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 20, 2024 Registration No.
November 20, 2024	EX-4.5	Form of Indenture EX-4.5 Exhibit 4.5 PMV PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Establi
November 14, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / ArrowMark Colorado Holdings LLC Passive Investment SC 13G/A 1 arrowmark-pmvp093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the
November 7, 2024	EX-99.1	PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results • Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 • PMV Pharmaceuticals is collabor
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commiss
August 14, 2024	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PMV PHARMACEUTICALS, INC. (Name of Subject Compan SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PMV PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.00001 par value (Title of Class of Securities) 69353Y103 (CUSIP
August 8, 2024	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commissio
August 8, 2024	EX-99.1	PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial • Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites activated across the U.S., Europe, and Asia-Pacific; interim anal
August 8, 2024	EX-10.1	Lease Termination Agreement, dated August 5, 2024, by and between BMR-One Research Way LLC and PMV Pharmaceuticals, Inc. Exhibit 10.1 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of this 5th day of August, 2024 (“Execution Date”), by and between BMR-ONE RESEARCH WAY LLC, a Delaware limited liability company (“Landlord”), and PMV PHARMACEUTICALS, Inc., a Delaware corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant entered into that certain Lease dated
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
July 16, 2024	EX-99.(A)(1)(B)	Launch Announcement. Exhibit (a)(1)(B) Email to All Eligible Employees From: David H. Mack, Ph.D., President and Chief Executive Officer, PMV Pharmaceuticals, Inc. To: All Eligible Employees Date: July 16, 2024 Subject: LAUNCH OF PMV’S STOCK OPTION EXCHANGE PROGRAM Dear PMV Eligible Employee: You are receiving this email because you are eligible to participate in a voluntary, one-time stock option exchange offer (the
July 16, 2024	SC TO-I	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PMV PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offe SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 PMV PHARMACEUTICALS, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.00001 par value (Title of Class of Securities) 69353Y103 (CUSIP Number of Class of Securities’ Underlying C
July 16, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form TO-I (Form Type) PMV Pharmaceuticals, Inc.
July 16, 2024	EX-99.(A)(1)(H)	Screenshots from Offer Website. Exhibit (a)(1)(h)
July 16, 2024	EX-99.(A)(1)(C)	Election Terms and Conditions. Exhibit (a)(1)(C) PMV PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION TERMS AND CONDITIONS 1. I agree that my decision to accept or reject the Offer with respect to some or all of my eligible option grants is entirely voluntary and is subject to the terms and conditions of the Offer. 2. I understand that I may change my election at any time
July 16, 2024	EX-99.(A)(1)(E)	Form of Reminder Email. Exhibit (a)(1)(E) Form of Reminder Email The PMV Pharmaceuticals, Inc. (“PMV”) offer to exchange certain outstanding stock options for new stock options (referred to as the “Offer”) currently is still open. Please note that the Offer will expire at 11:59 p.m., Eastern Time, on August 13, 2024, unless we extend the Offer. The Offer deadline will be strictly enforced, so we encourage you to give you
July 16, 2024	EX-99.(A)(1)(F)	Form of Expiration Notice Email. Exhibit (a)(1)(F) Form of Notice to Eligible Employees Regarding Expiration of Offering Period From: David H.
July 16, 2024	EX-99.(A)(1)(D)	Form of Confirmation Email. Exhibit (a)(1)(D) Form of Confirmation to Eligible Employees PMV Pharmaceuticals, Inc.
July 16, 2024	EX-99.(A)(1)(A)	Offer to Exchange Certain Outstanding Stock Options for New Stock Options, dated July 16, 2024. Exhibit (a)(1)(A) PMV PHARMACEUTICALS, INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the PMV Pharmaceuticals, Inc. 2020 Equity Incentive Plan. July 16, 2024 PMV PHARMACEUTICALS, INC. OFFER TO E
July 16, 2024	EX-99.(A)(1)(G)	Employee Presentation. Exhibit (a)(1)(g) Option Exchange Program Like Education & Information Session Begins: Tuesday, July 16, 2024 Ends: Tuesday, August 13, 2024, at 11:59 PM (ET) About Infinite Equity What We Do Who We Are We believe equity compensation programs Our highly experienced team can deliver should drive performance and fuel a wide range of technical expertise with innovation.
June 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2024 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission F
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission F
May 9, 2024	EX-10.4	2020 Employee Stock Purchase Plan and forms of agreements thereunder Exhibit 10.4 Updated as of: May 2024 PMV PHARMACEUTICALS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
May 9, 2024	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors • Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Me
April 24, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy S
April 24, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
April 9, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / JPMORGAN CHASE & CO - FILING PMV PHARMACEUTICALS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 04)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 29, 2024	EX-10.22	Amended and Restated Employment Letter, dated January 5, 2024, by and between the Registrant and Michael Carulli Exhibit 10.22 January 05, 2024 Michael Carulli c/o PMV Pharmaceuticals, Inc. Dear Mike, This letter agreement (the "Agreement" ) is entered into between you and PMV Pharmaceuticals, Inc. (the "Company," "PMV Pharma," or "we"), and amends and restates in full your earlier Employment Letter dated March 30, 2020, reflecting your promotion and related compensation changes. This Agreement is effective
February 29, 2024	EX-97.1	Compensation Recovery Policy Exhibit 97.1 FINAL PMV PHARMACEUTICALS, INC. COMPENSATION RECOVERY POLICY As adopted on July 26, 2023 PMV Pharmaceuticals, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Compensation Committee (“Compensation Committee”) of the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “
February 29, 2024	EX-10.23	Consulting Agreement, dated February 13, 2024, by and between the Registrant and Charles Baum, MD., Ph.D. Exhibit 10.23 PMV PHARMACEUTICALS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Agreement") is made and entered into by and between PMV PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and Charles Baum, M.D., Ph.D., an individual ("Consultant"), effective as of the date of last signature hereto ("Effective Date"). recitals WHEREAS, Consultant has unique skills and knowle
February 29, 2024	EX-10.24	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 5, 2024, by and between the Registrant and Michael Carulli Exhibit 10.24 Change in Control and Severance Policy (the "Policy") Amended and Restated Participation Agreement This Amended and Restated Participation Agreement ("Agreement") is made and entered into by and between Michael Carulli, on the one hand, and PMV Pharmaceuticals, Inc. (the "Company") on the other. In connection with your appointment as a Company officer, you are entitled to receive cer
February 29, 2024	EX-10.23	EX-10.23
February 29, 2024	EX-10.20	Consulting Agreement, dated January 5, 2024, by and between the Registrant and Winston Kung. Exhibit 10.20 PMV PHARMACEUTICALS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Winston Kung, an individual (“Consultant”), effective as of January 05, 2024 (“Effective Date”). RECITALS WHEREAS, Consultant is the Company’s former CFO/COO, and has unique skills and
February 29, 2024	EX-10.15	Amended Outside Director Compensation Policy. Exhibit 10.15 Reviewed & Updated by PMV Board as of: February 27, 2024 (“Updated Effective Date”) PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY PMV Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retai
February 29, 2024	EX-10.21	Separation Agreement, dated January 5, 2024, by and between the Registrant and Leila Alland, M.D. Exhibit 10.21 January 05, 2024 Via Email Dear Leila, This letter memorializes the terms and conditions for your separation from employment as the Chief Medical Officer for PMV Pharma (the "Company"), effective as of the date hereof (“Separation Date”). 1. Consideration. In consideration of your execution of this letter and your fulfillment of all of its terms and conditions, Company shall make the
February 29, 2024	EX-99.1	PMV Pharmaceuticals, Inc. Balance Sheets (in thousands) PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights • Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type, remains on track to initiate in Q1 2024 • Phase 1 analysis from the
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K c UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ! (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMAC
February 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commis
February 14, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / Avoro Capital Advisors LLC - PMV PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p24-0288sc13ga.htm PMV PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This State
February 14, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (the “Shares”) (Title of Class of Securities) 69353Y1
February 14, 2024	SC 13G	PMVP / PMV Pharmaceuticals, Inc. / ArrowMark Colorado Holdings LLC Passive Investment SC 13G 1 arrowmark-pmvp123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr
February 14, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / Boxer Capital, LLC Passive Investment SC 13G/A 1 ff302717113ga3-pmv.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Chec
February 14, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / RTW INVESTMENTS, LP - PMV PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p24-0438sc13ga.htm PMV PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this state
February 13, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01716-pmvpharmaceuticalsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: PMV Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 69353Y103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to
January 24, 2024	S-8	As filed with the Securities and Exchange Commission on January 24, 2024 As filed with the Securities and Exchange Commission on January 24, 2024 Registration No.
January 24, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PMV Pharmaceuticals, Inc.
January 23, 2024	SC 13G/A	PMVP / PMV Pharmaceuticals, Inc. / JPMORGAN CHASE & CO - FILING PMV PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 PMVPHARMACEUTICALSINC.ht.htm FILING PMV PHARMACEUTICALS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) December 29, 2023 (Date of Event Which Requires
January 18, 2024	EX-99.1	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway Exhibit 99.1 PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway • Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% • Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings fr
January 18, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commiss
January 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2024 PMV Pharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2024 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commissio
January 5, 2024	EX-99.1	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development Exhibit 99.1 PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development • PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) • Michael Carulli promoted to Chief Financial Officer • Robert Ticktin, General Coun
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
November 9, 2023	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights • Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven months • An overall response rate of 3
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commiss
October 12, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commiss
October 12, 2023	EX-99.2	Disclaimer Forward-Looking Statements This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected time KOL Webinar for Phase 1/2 PYNNACLE study of PC14586 from the 2023 AACR-NCI-EORTC International Conference October 12, 2023 Exhibit 99.
October 12, 2023	EX-99.1	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation Exhibit 99.1 PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation • Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics • Confirmed responses observed in multiple tumor types including ovarian, brea
October 11, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2023 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commiss
October 11, 2023	EX-99.1	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar Exhibit 99.1 PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar PRINCETON, N.J., October 11, 2023 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera
August 23, 2023	SC 13D/A	PMVP / PMV Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment SC 13D/A 1 ss2418229sc13da.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* PMV Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 69353Y103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC OrbiMed Genesis GP LLC 601 Lexington Avenue, 54th
August 23, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ss2418229ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to Schedule 13D, dated August 9, 2023, with respect to the common stock of PMV Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of
August 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 PMV Pharmaceutical UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commissio
August 9, 2023	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) Ex 99.1 PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights • Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; updated Phase 1 data expected in 2H 2023 • Concluded successful End-of-Phase 1 FDA meeting with alignment
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 PMV Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission F
May 19, 2023	SC 13G	PMVP / PMV Pharmaceuticals Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* PMV Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (the “Shares”) (Title of Class of Securities) 69353Y10
May 19, 2023	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of PMV Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under
May 10, 2023	EX-3	Amended and Restated Bylaws of the Registrant AMENDED AND RESTATED BYLAWS OF PMV PHARMACEUTICALS, INC. (initially adopted on August 5, 2020, and updated effective as of June 8, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDER
May 10, 2023	EX-99	PMV Pharmaceuticals, Inc. Balance Sheets (in thousands) Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights • Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023 • Commenced enrollment in the combination arm of the PYNNACLE s
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 PMV Pharmaceuticals, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
April 28, 2023	EX-3.1	Amended and Restated Bylaws of PMV Pharmaceuticals, Inc., effective June 8, 2023. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PMV PHARMACEUTICALS, INC. (initially adopted on August 5, 2020 and updated effective as of June 8, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOT
April 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2023 PMV Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2023 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission
April 28, 2023	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State
March 1, 2023	EX-99	PMV Pharmaceuticals, Inc. Balance Sheets (in thousands) Exhibit 99.1 PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights • Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023 • Enrolled first patient in combination arm of the
March 1, 2023	EX-10	Amended Outside Director Compensation Policy. Exhibit 10.15 Reviewed & Updated by PMV Board as of: February 24, 2023 (“Updated Effective Date”) PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY PMV Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retai
March 1, 2023	POSASR	Power of Attorney POSASR Table of Contents As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 PMV Pharmaceuticals UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
March 1, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ! (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEU
March 1, 2023	POS AM	As filed with the Securities and Exchange Commission on March 1, 2023 POS AM Table of Contents As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.
March 1, 2023	EX-FILING FEES	Calculation of Filing Fee Tables EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Post-Effective Amendment to Form S-3 (Form Type) PMV Pharmaceuticals, Inc.
February 14, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / RTW INVESTMENTS, LP - PMV PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p23-0512sc13ga.htm PMV PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this state
February 14, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Boxer Capital, LLC Passive Investment SC 13G/A 1 ff000174212013ga-pmv.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Ch
February 14, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (the “Shares”) (Title of Class of Securities) 69353Y1
February 14, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Avoro Capital Advisors LLC - PMV PHARMACEUTICALS, INC. Passive Investment SC 13G/A 1 p23-0576sc13ga.htm PMV PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This State
February 10, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / INTERWEST PARTNERS X LP - SC 13G/A Passive Investment SC 13G/A OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2010 Estimated average burden hours per response 10.
February 10, 2023	EX-99.A	Joint Filing Statement EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. Date: February 10, 2023 INTERWEST PARTNERS X, LP By: InterWest Management Partners X, LLC, its General Partner By: /s/ Karen A. Wilson, Power of Attorney Attorney-in-Fact INTERWEST MANAGEMENT PARTNERS X, LLC By: Karen A. Wilson, Power of Attorn
February 9, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01687-pmvpharmaceuticalsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: PMV Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 69353Y103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box t
January 25, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / JPMORGAN CHASE & CO - FILING PMV PHARMACEUTICALS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
January 25, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PMV Pharmaceuticals, Inc.
January 25, 2023	S-8	As filed with the Securities and Exchange Commission on January 24, 2023 As filed with the Securities and Exchange Commission on January 24, 2023 Registration No.
January 24, 2023	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G/A 1 pmvpa112423.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69353y103 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the ap
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
November 8, 2022	EX-99.1	PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights EX-99.1 2 pmvp-ex991.htm EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights • Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation • Phase 1b combination trial with Merck evaluating PC14586 with KEYTRUDA
November 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 PMV Pharmaceutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commiss
November 4, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commissi
November 4, 2022	EX-99.1	PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors Exhibit 99.1 PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors CRANBURY, N.J., November 4, 2022 (GLOBE NEWSWIRE) ? PMV Pharmaceuticals, Inc. (?PMV Pharma? or ?PMV?; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, P
August 9, 2022	EX-10.15	Outside Director Compensation Policy., as amended on May 5, 2022 Exhibit 10.15 Reviewed & Updated by PMV Board as of: May 05, 2022 (?Updated Effective Date?) PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY PMV Pharmaceuticals, Inc. (the ?Company?) believes that providing cash and equity compensation to its members of the Board of Directors (the ?Board,? and members of the Board, the ?Directors?) represents an effective tool to attract, retain and
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
August 9, 2022	EX-99.1	PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights ? Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation ? Entered into a clinical collaboration with Merck to evaluate PC14586 in combination with KE
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commissio
July 7, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / JPMORGAN CHASE & CO - FILING PMV PHARMACEUTICALS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
June 17, 2022	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of PMV Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under
June 17, 2022	SC 13G	PMVP / PMV Pharmaceuticals Inc / CITADEL ADVISORS LLC - PMV PHARMACEUTICALS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* PMV Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (the ?Shares?) (Title of Class of Securities) 69353Y10
June 8, 2022	EX-99.1	PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation EX-99.1 2 d274688dex991.htm EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation • Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 • Partial responses observed across six distinct tumor types • Data featured as an oral presentatio
June 8, 2022	EX-99.2	Disclaimer Forward-Looking Statements This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected time Exhibit 99.2 ASCO PC14586 INVESTOR EVENT June 7, 2022 Disclaimer Forward-Looking Statements This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for PC14586 and our pipeline programs, plans regarding regulatory filings, our expectation
June 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
June 6, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission F
May 26, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
May 26, 2022	EX-99.1	PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Exhibit 99.1 PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting ? Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ? ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and activity observed in multiple tumo
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
May 10, 2022	EX-10.14	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated March 24, 2022, by and between the Registrant and Deepika Jalota, Pharm.D. Exhibit 10.14 Change in Control and Severance Policy Amended and Restated Participation Agreement This Amended and Restated Participation Agreement (?Agreement?) is made and entered into by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the ?Company?) on the other. In connection with your recent promotion to be the Company?s Chief Regulatory and Quality Officer, you are
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
May 10, 2022	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights ? Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the d
April 22, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Prox
April 22, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? D
April 1, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated March 29, 2022, with respect to the ordinary shares of PMV Pharmaceuticals, Inc.
April 1, 2022	SC 13D/A	PMVP / PMV Pharmaceuticals Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 69353Y103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 T
March 1, 2022	EX-10.8	Employment Offer Letter, dated February 22, 2021, by and between the Registrant and Deepika Jalota, Pharm.D. Exhibit 10.8 February 22, 2021 Deepika Jalota, Pharm.D. c/o PMV Pharmaceuticals, Inc. Dear Deepika, This letter agreement (the ?Agreement?) is entered into between you and PMV Pharmaceuticals, Inc. (the ?Company,? ?PMV Pharma,? or ?we?), and amends and restates in full your earlier Employment Letter dated August 11, 2020, reflecting your promotion and related compensation changes. This Agreement i
March 1, 2022	EX-10.14	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 14, 2022, by and between the Registrant and Deepika Jalota, Pharm.D. Exhibit 10.14 Change in Control and Severance Policy Amended and Restated Participation Agreement This Amended and Restated Participation Agreement ("Agreement") is made and entered into by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the "Company") on the other. In connection with your recent promotion to be the Company's Chief Regulatory and Quality Officer, you are
March 1, 2022	EX-10.17	Consulting Agreement, dated May 21, 2021, by and between the Registrant and Richard Heyman, Ph.D., as amended on July 16, 2021 Exhibit 10.17 PMV PHARMACEUTICALS, INC. AMENDED & RESTATED SAB CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made and entered into by and between PMV PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and Richard Heyman, Ph.D., an individual (?Consultant?), effective as of May 15, 2021 (?Effective Date?). RECITALS WHEREAS, Consultant and the Company have previousl
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ! (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEU
March 1, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None.
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
March 1, 2022	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Balance Sheets (unaudited, in thousands) Exhibit 99.1 PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights ? Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutation ? Strong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 202
February 14, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / INTERWEST PARTNERS X LP - SC 13G/A Passive Investment SC 13G/A OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2010 Estimated average burden hours per response 10.
February 14, 2022	EX-99.A	Joint Filing Statement EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us.
February 14, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Euclidean Capital LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 69353Y 103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 14, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A 1 d238590dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement)
February 14, 2022	EX-99.2	Power of Attorney EXHIBIT 2 Power of Attorney Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Julia E.
February 14, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Nextech V Oncology S.C.S., SICAV-SIF - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 69353Y 10 3 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 14, 2022	EX-99.1	Power of Attorney EX-99.1 EXHIBIT 1 Power of Attorney Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Julia E. Herr and Joseph Cosmai, or either of them acting singly, and with full power of substitution and re-substitution, the undersigned’s true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the “Attorney-in-Fact”
February 14, 2022	EX-99.3	Power of Attorney EXHIBIT 3 Power of Attorney Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Julia E.
February 14, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) PMV Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103
February 14, 2022	SC 13G	PMVP / PMV Pharmaceuticals Inc / RTW INVESTMENTS, LP - PMV PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu
February 11, 2022	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Avoro Capital Advisors LLC - PMV PHARMACEUTICALS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu
February 10, 2022	SC 13G	PMVP / PMV Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: PMV Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 69353Y103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b)
January 26, 2022	SC 13G	PMVP / PMV Pharmaceuticals Inc / JPMORGAN CHASE & CO - FILING PMV PHARMACEUTICALS, INC. Passive Investment SC 13G 1 PMVPHARMACEUTICALSINC.ht.htm FILING PMV PHARMACEUTICALS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fili
January 24, 2022	S-8	As filed with the Securities and Exchange Commission on January 24, 2022 As filed with the Securities and Exchange Commission on January 24, 2022 Registration No.
January 19, 2022	SC 13G	PMVP / PMV Pharmaceuticals Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PMV Pharmaceuticals, Inc. (Name of Issuer) PMV Pharmaceuticals, Inc. (Title of Class of Securities) 69353y103 (CUSIP Number) January 14, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
January 6, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2022 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commissio
January 6, 2022	EX-99.1	PMV Pharma Announces Changes to its Board of Directors Exhibit 99.1 PMV Pharma Announces Changes to its Board of Directors CRANBURY, NJ, January 06, 2022 (GLOBE NEWSWIRE) ? PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the app
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
November 12, 2021	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights CRANBURY, NJ, November 12, 2021 (GLOBE NEWSWIRE) ? PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies designed to activate p53 function, today reported financial results for the third quarter ended Septe
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commis
October 18, 2021	SC 13G/A	PMVP / PMV Pharmaceuticals Inc / Euclidean Capital LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 69353Y 103 (CUSIP Number) October 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
October 5, 2021	EX-1.1	Open Market Sale Agreement, between the Company and Jefferies LLC, dated as of October 4, 2021. Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM October 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: PMV Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s commo
October 5, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 4, 2021 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commissio
October 4, 2021	S-3ASR	As filed with the Securities and Exchange Commission on October 4, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 4, 2021 Registration No.
October 4, 2021	EX-1.2	Open Market Sale Agreement, dated as of October 4, 2021, between the Registrant and Jefferies LLC EX-1.2 2 d231282dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM October 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: PMV Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent
October 4, 2021	EX-4.4	Form of Indenture Exhibit 4.4 PMV PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment o
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
August 13, 2021	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights ? Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586 CRANBURY, NJ, August 13, 2021 (GLOBE NEWSWIRE) ? PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap
August 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commissi
June 7, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2021 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission F
May 21, 2021	S-8	As filed with the Securities and Exchange Commission on May 21, 2021 As filed with the Securities and Exchange Commission on May 21, 2021 Registration No.
May 14, 2021	EX-99.1	PMV Pharmaceuticals, Inc. Consolidated Balance Sheet Data (unaudited, in thousands) Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights ? Presented late breaking preclinical data on PC14586, the Company?s first-in-class, tumor-agnostic, investigational small molecule p53 Y220C reactivator at the American Association for Cancer Research Annual Meeting 2021 ? Expanded Board of Directors with the appointment of Charles M. Baum, M.D.
May 14, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 pmvp-8k20210514.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction
May 14, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
May 7, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securit UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 69353Y 103 (CUSIP Number) April 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
April 23, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Prox
April 23, 2021	DEF 14A	Schedule 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 6, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2021 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Commission
April 6, 2021	EX-99.1	PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum EX-99.1 2 d137028dex991.htm EX-99.1 Exhibit 99.1 PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum CRANBURY, NJ, April 6, 2021 (GLOBE NEWSWIRE) – PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Charles M
March 3, 2021	EX-99.1	PMV Pharmaceuticals, Inc. Consolidated Balance Sheet Data (unaudited, in thousands) EX-99.1 2 pmvp-ex99120.htm EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights • Initiated Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutation • PC14586 granted Fast Track designation by the U.S. FDA • Appointed Deepika
March 3, 2021	EX-10.19	Lease Agreement, dated January 8, 2021, by and between the Registrant and BMR-ONE RESEARCH WAY LLC. Exhibit 10.19 LEASE by and between BMR-ONE RESEARCH WAY LLC, a Delaware limited liability company and PMV PHARMACEUTICALS, INC., a Delaware corporation Table of Contents 1. Lease of Premises. 1 2. Basic Lease Provisions 1 3. Term 5 4. Possession and Commencement Date. 5 5. Condition of Premises 6 6. Rent 7 7. Rent Adjustments 7 8. Taxes 8 9. Property Management Fee 9 10. Security Deposit 9 11. Use
March 3, 2021	EX-4.1	Exhibit 4.1 EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by t
March 3, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commission
March 3, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTI
February 16, 2021	EX-99.1	JOINT FILING STATEMENT EX-99.1 2 tm216872d3ex99-1.htm EXHIBIT 99.1 CUSIP No. 49705R 10 5 13G Exhibit 99.1 JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of PMV Pharmaceuticals, Inc. is filed on behalf of each of us. Dated: February 16, 2021 Nextech V Oncology S.C.S., SICAV-SIF By: Nextech V GP S.à r.l. Its: General Partner
February 16, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 693 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y 10 3 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 16, 2021	SC 13G/A	SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) PMV Pharmaceuticals, Inc. (Name of Issuer) Comm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) PMV Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 69353Y10
February 12, 2021	SC 13G	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2010 Estimated average burden hours per response 10.
February 12, 2021	SC 13G	PMV Pharmaceuticals, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 69353Y103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu
February 12, 2021	EX-99.A	Joint Filing Statement EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. Date: February 12, 2021 INTERWEST PARTNERS X, LP By: InterWest Management Partners X, LLC, its General Partner By: /s/ Karen A. Wilson, Power of Attorney Attorney-in-Fact INTERWEST MANAGEMENT PARTNERS X, LLC By: /s/ Karen A. Wilson, Power of At
February 12, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 69353Y 103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
November 13, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 PMV Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39539 46-3218129 (State or Other Jurisdiction of Incorporation) (Commis
November 13, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC.
November 13, 2020	EX-99.1	PMV Pharmaceuticals, Inc. Condensed Consolidated Balance Sheet Data (Unaudited) (in thousands) Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights November 13, 2020 • U.S. Food and Drug Administration (FDA) clearance of PMV Pharmaceutical’s investigational new drug application for its lead product candidate PC14586 • PMV Pharma lead product candidate PC14586 granted Fast Track designation by the FDA • Expanded Board of Directors with appoin
October 5, 2020	SC 13G	PMVP / PMV Pharmaceuticals, Inc. / VIKING GLOBAL INVESTORS LP - ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* PMV Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103 (CUSIP Number) Sep
October 5, 2020	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated October 5, 2020, with respect to the ordinary shares of PMV Pharmaceuticals, Inc.
October 5, 2020	SC 13D	PMVP / PMV Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 PMV Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 69353Y103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739
September 30, 2020	SC 13G	PMVP / PMV Pharmaceuticals, Inc. / Boxer Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PMV Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 69353Y103 (CUSIP Number) September 25, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de
September 30, 2020	EX-99.1	JOINT FILING AGREEMENT EX-99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of PMV Pharmaceuticals, Inc., $0.00001 par value per share, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as am
September 29, 2020	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2020 PMV Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39539 46-3218129 (State or other jurisdiction of incorporation) (Co
September 29, 2020	EX-3.1	Amended and Restated Certificate of Incorporation of the Registrant EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PMV PHARMACEUTICALS, INC. a Delaware corporation PMV Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The Company was originally incorporated under the name of PJ Pharmaceuticals, Inc., and the original Certificate of Incorpo
September 29, 2020	EX-3.2	Amended and Restated Bylaws of the Registrant EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PMV PHARMACEUTICALS, INC. (initially adopted on August 5, 2020) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 7 2.6 QUORU
September 29, 2020	EX-99.1	PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares EX-99.1 Exhibit 99.1 PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares CRANBURY, New Jersey, September 29, 2020 (GLOBE NEWSWIRE) –- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, to
September 28, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on September 28, 2020 Registration No.
September 25, 2020	424B4	11,765,000 Shares Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-248627 PROSPECTUS 11,765,000 Shares Common Stock This is an initial public offering of shares of common stock of PMV Pharmaceuticals, Inc. All of the 11,765,000 shares of common stock are being sold by the company. Prior to this offering, there has been no public market for our common stock. The initial public offering p
September 24, 2020	S-1/A	Form S-1 S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 24, 2020.
September 22, 2020	CORRESP	- CORRESP September 22, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Ameen Hamady Kevin Kuhar Deanna Virginio Dorrie Yale Re: PMV Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-248627 Acceleration Request Requested Date: Thursday, September 24, 2020 Requested
September 22, 2020	CORRESP	- CORRESP September 22, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Ameen Hamady Kevin Kuhar Deanna Virginio Dorrie Yale Re: PMV Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-248627 Acceleration Request Requested Date: September 24, 2020 Requested Time: 4
September 21, 2020	CORRESP	- CORRESP 1301 Avenue of the Americas, 40th Floor New York, NY 10019-6022 PHONE 212.
September 21, 2020	8-A12B	Form 8-A 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PMV PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-3218129 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identific
September 21, 2020	EX-10.15	Outside Director Compensation Policy. EX-10.15 Exhibit 10.15 PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved by the Board of Directors on August 5, 2020 PMV Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and rewa
September 21, 2020	EX-3.1	Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PMV PHARMACEUTICALS, INC. PMV Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is PMV Pharmaceuticals, Inc. The Corporation was originally incorporated under the name “PJ Pharmaceuticals, Inc.” The origi
September 21, 2020	EX-4.2	Specimen common stock certificate of the Registrant EX-4.2 Exhibit 4.2 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 69353Y 10 3 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.00001 PAR VALUE PER SHARE, OF PMV PHARMACEUTICALS, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate prope
September 21, 2020	S-1/A	- S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 21, 2020.
September 21, 2020	EX-10.4	2020 Employee Stock Purchase Plan and forms of agreements thereunder EX-10.4 8 d922470dex104.htm EX-10.4 Exhibit 10.4 PMV PHARMACEUTICALS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “emp
September 21, 2020	EX-10.3	2020 Equity Incentive Plan and forms of agreements thereunder EX-10.3 Exhibit 10.3 PMV PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive S
September 21, 2020	EX-10.2	2013 Equity Incentive Plan, as amended, and form agreement thereunder EX-10.2 Exhibit 10.2 PMV PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive S
September 21, 2020	EX-1.1	Form of Underwriting Agreement, including Form of Lock-up Agreement. EX-1.1 2 d922470dex11.htm EX-1.1 Exhibit 1.1 PMV Pharmaceuticals, Inc. [●] Shares of Common Stock Underwriting Agreement [●], 2020 Goldman Sachs & Co. LLC BofA Securities, Inc. Cowen and Company, LLC Evercore Group L.L.C. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o B
September 11, 2020	CORRESP	- CORRESP 1301 Avenue of the Americas, 40th Floor New York, NY 10019-6022 PHONE 212.
September 4, 2020	EX-10.10	Change in Control and Severance Policy. EX-10.10 Exhibit 10.10 PMV Pharmaceuticals, Inc. Change in Control and Severance Policy This Change in Control and Severance Policy (the “Policy”) is designed to provide certain protections to a select group of key employees of PMV Pharmaceuticals, Inc. (“PMV Pharmaceuticals” or the “Company”) or any of its subsidiaries if their employment is involuntary terminated under the circumstances describe
September 4, 2020	EX-10.17	Consulting Agreement, dated July 14, 2017, by and between the Registrant and Richard Heyman, Ph.D. EX-10.17 Exhibit 10.17 PMV PHARMA CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMA, a Delaware corporation (the “Company”), and Richard Heyman, Ph.D., an individual (“Consultant”), effective as of the date of last signature hereto (“Effective Date”). RECITALS WHEREAS, Consultant has unique skills and knowledge in the Company’s fiel
September 4, 2020	EX-10.18	Lease Agreement, dated March 3, 2015, by and between the Registrant and Cedar Brook 2005, LP, as amended by the First Amendment to Lease dated April 24, 2017. EX-10.18 Exhibit 10.18 LEASE AGREEMENT BY AND BETWEEN: Cedar Brook 2005, LP “Landlord” and - PMV Pharmaceuticals, Inc. “Tenant” PREMISES: 8 Clarke Drive, Cranbury, NJ 08512 DATED: February , 2015 Contents 1. LEASED PREMISES 1 2. TERM OF LEASE 1 3. CONSTRUCTION OF THE TENANT IMPROVEMENTS 2 4. RENT 2 5. PARKING AND USE OF EXTERIOR AREA 3 6. USE 3 7. REPAIRS AND MAINTENANCE 3 8. COMMON AREA EXPENSES,
September 4, 2020	EX-4.1	Amended and Restated Investors’ Rights Agreement, dated July 17, 2020, by and among the Registrant and certain of its stockholders EX-4.1 Exhibit 4.1 PMV PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 17, 2020 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 5 2.1 Requested Registration 5 2.2 Company Registration 7 2.3 Registration on Form S-3 9 2.4 Expenses of Registration 9 2.5 Registration Procedures 10 2.6 Indemnification 12 2.7 Information
September 4, 2020	EX-10.5	Employment Offer Letter, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D. EX-10.5 Exhibit 10.5 August 11, 2020 David H. Mack, Ph.D. c/o PMV Pharmaceuticals, Inc. Dear David, This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”). This Agreement is effective as of the date hereof (the “Effective Date”). The purpose of this Agreement is to confirm the current terms and conditions of your emp
September 4, 2020	EX-10.4	2020 Employee Stock Purchase Plan and forms of agreements thereunder, to be in effect upon the completion of this offering. EX-10.4 Exhibit 10.4 PMV PHARMACEUTICALS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” u
September 4, 2020	EX-10.14	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 18, 2020, by and between the Registrant and Deepika Jalota, Pharm.D. EX-10.14 Exhibit 10.14 Change in Control and Severance Policy Amended and Restated Participation Agreement This Amended and Restated Participation Agreement (“Agreement”) is made and entered into by and between Deepika Jalota on the one hand, and PMV Pharmaceuticals, Inc. (the “Company”) on the other. In connection with the Company’s anticipated initial public offering, the Compensation Committee
September 4, 2020	EX-10.12	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 17, 2020, by and between the Registrant and Winston Kung. EX-10.12 Exhibit 10.12 Change in Control and Severance Policy Amended and Restated Participation Agreement This Amended and Restated Participation Agreement (“Agreement”) is made and entered into by and between Winston Kung on the one hand, and PMV Pharmaceuticals, Inc. (the “Company”) on the other. In connection with the Company’s anticipated initial public offering, the Compensation Committee of
September 4, 2020	EX-10.6	Employment Offer Letter, dated August 17, 2020, by and between the Registrant and Winston Kung EX-10.6 Exhibit 10.6 August 11, 2020 Winston Kung c/o PMV Pharmaceuticals, Inc. Dear Winston, This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”). This Agreement is effective as of the date hereof (the “Effective Date”). The purpose of this Agreement is to confirm the current terms and conditions of your employmen
September 4, 2020	EX-10.3	2020 Equity Incentive Plan and forms of agreements thereunder, to be in effect prior to the completion of this offering. EX-10.3 Exhibit 10.3 PMV PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive S
September 4, 2020	EX-10.16	Consulting Agreement, dated January 1, 2016, by and between the Registrant and Arnold Levine, Ph.D. EX-10.16 Exhibit 10.16 PMV PHARMA CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMA, a Delaware corporation (the “Company”), and Arnold Levine, Ph.D., an individual (“Consultant”), effective as of January 1, 2016 (“Effective Date”). RECITALS WHEREAS, Consultant has unique skills and knowledge in the Company’s field of endeavor and t
September 4, 2020	EX-10.13	Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 18, 2020, by and between the Registrant and Leila Alland, M.D. EX-10.13 Exhibit 10.13 Change in Control and Severance Policy Amended and Restated Participation Agreement This Amended and Restated Participation Agreement (“Agreement”) is made and entered into by and between Leila Alland on the one hand, and PMV Pharmaceuticals, Inc. (the “Company”) on the other. In connection with the Company’s anticipated initial public offering, the Compensation Committee of
September 4, 2020	EX-10.15	Outside Director Compensation Policy. EX-10.15 Exhibit 10.15 PMV PHARMACEUTICALS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved by the Board of Directors on August 5, 2020 PMV Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and rewa
September 4, 2020	EX-3.4	Form of Amended and Restated Bylaws of the Registrant, to be in effect immediately prior to the completion of this offering. EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF PMV PHARMACEUTICALS, INC. (initially adopted on August 5, 2020) (effective as of the closing of the company’s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVAN
September 4, 2020	EX-3.3	Bylaws of the Registrant, as currently in effect. EX-3.3 Exhibit 3.3 BYLAWS OF PMV PHARMACEUTICALS, INC. Adopted June 25, 2013 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Reco
September 4, 2020	EX-10.7	Employment Offer Letter, dated August 18, 2020, by and between the Registrant and Leila Alland, M.D. EX-10.7 Exhibit 10.7 August 11, 2020 Leila Alland, M.D. c/o PMV Pharmaceuticals, Inc. Dear Leila, This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”). This Agreement is effective as of the date hereof (the “Effective Date”). The purpose of this Agreement is to confirm the current terms and conditions of your emplo
September 4, 2020	EX-10.8	Employment Offer Letter, dated August 18, 2020, by and between the Registrant and Deepika Jalota, Pharm.D. EX-10.8 Exhibit 10.8 August 11, 2020 Deepika Jalota, Pharm.D. c/o PMV Pharmaceuticals, Inc. Dear Deepika, This letter agreement (the “Agreement”) is entered into between you and PMV Pharmaceuticals, Inc. (the “Company,” “PMV Pharma,” or “we”). This Agreement is effective as of the date hereof (the “Effective Date”). The purpose of this Agreement is to confirm the current terms and conditions of yo
September 4, 2020	EX-3.2	Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect immediately prior to the completion of this offering. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PMV PHARMACEUTICALS, INC. a Delaware corporation PMV Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The Company was originally incorporated under the name of PJ Pharmaceuticals, Inc., and the original Certificate of Incorpo
September 4, 2020	S-1	Power of Attorney (see page II-7 to Form S-1 filed with the SEC on September 4, 2020). S-1 Table of Contents As filed with the Securities and Exchange Commission on September 4, 2020.
September 4, 2020	EX-10.9	Employee Incentive Compensation Plan. EX-10.9 Exhibit 10.9 PMV PHARMACEUTICALS, INC. EMPLOYEE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (i) perform to the best of their abilities and (ii) achieve the Company’s objectives. 2. Definitions. (a) “Actual Award” means as to any Performance Period, the actual award (if any)

PMVP / PMV Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)